DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. (August 2013)

• Record Type: Journal Article
• Authors: Terrazzino, Salvatore; Cargnin, Sarah; Del Re, Marzia; Danesi, Romano; Canonico, Pier Luigi; Genazzani, Armando A
• Is Part Of: Pharmacogenomics. Volume 14:Number 11(2013)
• Page Start: 1255
• Page End: 1272
• Publication Date: 2013-08
• Subjects: DPYD -- fluoropyrimidines -- meta-analysis -- pharmacogenetics -- risk factors -- toxicity; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs.13.116
• Languages: English
• ISSNs: 1462-2416

Abstract

Aim: In the present study we conducted a systematic review and meta-analysis of published data to quantify the impact of the DPYD IVS14+1G>A and 2846A>T variants on the risk of fluoropyrimidine-related toxicities and to determine sensitivity and specificity testing for DPYD variants.Methods: Relevant studies were identified through PubMed and Web of Knowledge databases, studies included were those published up until to May 2012. Study quality was assessed according to the HuGENET guidelines and Strengthening the Reporting of Genetic Association (STREGA) recommendations.Results: Random-effects meta-analysis provided evidence that carriers of DPYD IVS14+1G>A are at higher risk of ≥3 degrees of overall grade toxicity, hematological toxicity, mucositis and diarrhea. In addition, a strong association was also found between carriers of the DPYD 2846T allele and overall grade ≥3 toxicity or grade ≥3 diarrhea. An inverse linear relationship was found in prospective studies between the odds ratio of DPYD IVS14+1G>A and the incidence of overall grade ≥3 toxicity, indicating an higher impact in cohorts in which the incidence of severe toxicity was lower.Conclusion: The results of this meta-analysis confirm clinical validity of DPYD IVS14+1G>A and 2846A>T as risk factors for the development of severe toxicities following fluoropyrimidine treatment. Furthermore, the sensitivity and specificity estimates obtained could be useful in establishing the cost–effectiveness of testing for DPYD variants. Original submitted 4 March 2013; Revision submitted 17 June 2013